The US Food and Drug Administration (FDA) recently approved pharma giants Sanofi and Merck’s Vaxelis, a new pediatric vaccine against six diseases. The vaccine will help to bolster vaccination rates across the US by reducing the shot burden on infants and children, according to GlobalData, a leading data
James Mather, Pharma Analyst at GlobalData, says: “Vaxelis’ approval in the US is a major regulatory breakthrough, as the FDA has been more hesitant than the European Medicines Agency (EMA), which approved Vaxelis in 2015, in the acceptance of high-valiancy diphtheria, tetanus, and acellular pertussis (DTaP) vaccines.”
Unlike its rival six-in-one vaccine in Europe, GlaxoSmithKline’s (GSK’s) Infanrix Hexa (DTaP-IPV-HepB/Hib), Vaxelis is fully liquid and therefore does not require reconstitution, providing a more convenient route of administration for physicians and their office staff.
Visit For More Reports on Vaccines: https://dpiresearch.com/